Yahoo
    LSE - Delayed Quote GBp

    Shield Therapeutics plc (STX.L)

    3.0500 -2.4500 (-44.55%)
    At close: 5:10:53 PM GMT
    STX.L Q3 2026 earnings call
    Replay the call for the latest insights.
    Loading Chart for STX.L
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Shield Therapeutics loses profitability target as Medicaid pressures offset prescription growth

    Shield Therapeutics loses profitability target as Medicaid pressures offset prescription growth
    Proactive 11h ago
    Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris

    Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris
    Proactive 2mo ago
    Shield Therapeutics jumps 11% as losses narrow and profitability target held

    Shield Therapeutics jumps 11% as losses narrow and profitability target held
    Proactive 2mo ago
    Shield Therapeutics plc's (LON:STX) Path To Profitability

    Shield Therapeutics plc's (LON:STX) Path To Profitability
    Simply Wall St. 5mo ago
    Shield Therapeutics drops as CFO exits and Medicaid concerns weigh

    Shield Therapeutics drops as CFO exits and Medicaid concerns weigh
    Proactive 6mo ago
    Foresee Pharmaceuticals Appoints Brian J. Groch as Chief Commercial Officer to Spearhead Commercial Launch of FP-001 42 mg for Central Precocious Puberty

    Foresee Pharmaceuticals Appoints Brian J. Groch as Chief Commercial Officer to Spearhead Commercial Launch of FP-001 42 mg for Central Precocious Puberty
    PR Newswire 3mo ago
    ProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for Rilparencel

    ProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for Rilparencel
    Insider Monkey 6mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: